Testosterone replacement therapy for females is one of the most under-discussed tools in women's hormonal health — clinically supported, frequently overlooked, and often misunderstood by both patients and providers.

Key Takeaways
  • Testosterone therapy addresses low libido, fatigue, brain fog, and muscle loss that estrogen and progesterone alone may not resolve.
  • Women's testosterone levels drop by up to 50% between ages 20 and 45.
  • Free testosterone, not total, is the clinically meaningful number, and it must be read on female-specific reference ranges.
  • The strongest evidence is for hypoactive sexual desire disorder (HSDD); other uses remain off-label in 2026.
  • Start low, titrate slowly, and assess response over 8–12 weeks, not at 4 weeks.
By the Numbers
15–70 ng/dL
target total testosterone range for women on therapy
1–10 mg/day
typical low-dose testosterone therapy for women
up to 50%
decline in women's testosterone between ages 20 and 45
8–12 weeks
minimum window to assess response
Clinical note

Without SHBG, free testosterone cannot be accurately interpreted, and a normal total testosterone result can mask clinically low bioavailable levels. Ordering testosterone alone without SHBG is the most common lab mistake.

TL;DR: Testosterone replacement therapy for females addresses low libido, fatigue, brain fog, and muscle loss — symptoms that estrogen and progesterone therapy alone don't always resolve. Women produce testosterone in their ovaries and adrenal glands, and levels drop by up to 50% between ages 20 and 45. In 2026, low-dose testosterone therapy (typically 1–10 mg/day) is prescribed off-label in the US, with strong evidence for sexual dysfunction and emerging evidence for mood, cognition, and body composition. It is not appropriate for everyone, and side effects at the wrong dose are real. Good Life Health offers hormone optimization that includes testosterone assessment for women.

Why This Matters

Most women entering perimenopause or menopause are offered estrogen and progesterone. Testosterone rarely gets mentioned, even though the International Menopause Society issued a global consensus statement in 2019 affirming testosterone therapy's evidence base for hypoactive sexual desire disorder (HSDD) in women. By 2026, awareness has grown — but the gap between evidence and prescription practice remains wide. If your symptoms include low libido, unexplained fatigue, or difficulty building muscle despite exercise, testosterone levels deserve a look.

What You'll Need

  • A baseline blood panel: total testosterone, free testosterone, SHBG (sex hormone-binding globulin), estradiol, and DHEA-S
  • A provider who understands female-specific dosing (standard male reference ranges do not apply)
  • 8–12 weeks of patience — this is the minimum window to assess response
  • Honest symptom tracking before and after starting therapy
  • An understanding of the available delivery forms and their trade-offs (covered in Step 3 below)

The Steps

Step 1: Get a Symptom-Informed Baseline Lab Panel

Start with blood work, not a prescription. A complete panel measures total testosterone, free testosterone, SHBG, DHEA-S, LH, FSH, and estradiol. Free testosterone — the fraction not bound to SHBG — is the clinically meaningful number. Many women test within the standard lab range on total testosterone but show low free testosterone because SHBG is elevated.

The target range for women on therapy is generally 15–70 ng/dL for total testosterone, compared to 300–1000 ng/dL for men. If your provider is using male reference ranges to evaluate your results, that's a problem worth flagging.

Common mistake: Ordering testosterone alone without SHBG. Without SHBG, free testosterone cannot be accurately interpreted, and a normal total testosterone result can mask clinically low bioavailable levels.

Step 2: Confirm the Clinical Indication

Testosterone therapy for women is approved by multiple international medical societies for one primary indication: hypoactive sexual desire disorder (HSDD). Evidence also supports its use for fatigue, mood instability, and muscle mass preservation — but these are off-label in 2026.

You and your provider need to establish whether symptoms are testosterone-driven or explained by another cause (thyroid dysfunction, iron deficiency, sleep apnea, or estrogen deficiency all mimic low-T symptoms). Treating the wrong root cause wastes time and exposes you to unnecessary side effects.

Common mistake: Starting testosterone when estrogen deficiency is the actual driver. Estrogen should typically be optimized first in peri- and post-menopausal women before adding testosterone.

Step 3: Choose the Right Delivery Form

No FDA-approved testosterone product exists specifically for women in the US as of 2026. All female testosterone therapy is prescribed off-label. The three main options are:

  • Transdermal cream or gel (compounded, 1–10 mg/day): Most commonly prescribed for women. Applied to the inner arm or thigh. Allows precise dose titration. Absorption varies 10–20% between individuals.
  • Testosterone pellets (subcutaneous, 75–150 mg per insertion): Inserted under the skin every 3–6 months. Convenience is high; reversibility is low. Overdose risk is real because you cannot remove a pellet mid-cycle.
  • Testosterone injections (compounded, micro-dosed): Less common for women due to the sharper peak-and-trough cycle. Some providers use it for women who don't absorb topicals well.

For most women starting therapy in 2026, a compounded transdermal cream at the lowest effective dose is the standard starting point. Pellets are appropriate only after you've confirmed response and dose tolerance with a titratable form.

Common mistake: Starting with pellets before establishing your ideal dose. If you experience androgenic side effects — acne, hair thinning, clitoral enlargement, voice changes — you cannot reverse a pellet. You can stop a cream.

Step 4: Start Low and Titrate Slowly

The standard starting dose for female testosterone therapy is 1–2 mg/day transdermal. This is 10–30 times lower than a typical male starting dose. Increases happen in 1–2 mg increments, no faster than every 8 weeks.

Expected timeline:

  • Weeks 1–4: Few noticeable changes. Tissue is equilibrating.
  • Weeks 4–8: Many women report improved energy and early libido changes.
  • Weeks 8–12: The clearest window for symptom response assessment.
  • Months 3–6: Body composition changes (modest lean mass increase, modest fat redistribution) become measurable.

Blood levels should be re-checked at 6–8 weeks. Target free testosterone in the upper quartile of the normal female range — not above it.

Common mistake: Increasing dose because symptoms haven't fully resolved at 4 weeks. Eight weeks is the minimum assessment window. Premature dose escalation is the most common driver of androgenic side effects in women.

Step 5: Monitor and Adjust Every 6 Months

Once a stable dose is established, recheck labs every 6 months: testosterone, SHBG, hematocrit, and lipids. Hematocrit elevation is far more pronounced in men, but it can occur in women on higher doses. Lipid monitoring matters because some testosterone formulations (particularly oral and injectable) can suppress HDL cholesterol.

Symptom tracking is as important as bloodwork. Use a validated instrument like the Female Sexual Function Index (FSFI) or the Menopause Rating Scale (MRS) at baseline and at each follow-up. Numbers anchor the clinical conversation and justify continued therapy or dose adjustment.

Common mistake: Relying on symptoms alone without lab confirmation. A woman who feels great on a high dose may have supraphysiologic testosterone levels that pose long-term cardiovascular and androgenic risk.

Step 6: Know When to Stop

Testosterone therapy for women is not indefinite by default. Re-evaluate annually whether the original indication still applies. Women who started therapy for HSDD during perimenopause may find that optimizing estrogen after menopause reduces the testosterone requirement.

Stop therapy promptly if androgenic side effects appear (new acne, scalp hair loss, clitoromegaly, or voice deepening) — these are dose-related and typically reversible if caught early. Discontinuation means symptoms may return, but they can be retested and a revised protocol started.

Troubleshooting

No symptom improvement after 12 weeks at starting dose First rule out: inadequate absorption (switch delivery route before increasing dose), estrogen deficiency driving the fatigue or low libido, or a non-hormonal cause like depression or sleep disorder. Only then consider a dose increase.

Acne or oily skin within weeks of starting This is a dose signal, not an allergy. Reduce dose by 50% and hold for 4 weeks. If acne resolves, titrate back up more slowly. If it persists at the lowest dose, this formulation is not tolerable for your skin type — consider switching to a different vehicle.

Labs show supraphysiologic levels but you feel fine Feel-good does not equal safe. Sustained supraphysiologic testosterone in women is associated with polycythemia risk, lipid disruption, and androgenic changes that can become permanent (voice, clitoromegaly). Reduce dose regardless of subjective wellbeing.

SHBG is very high and free testosterone stays low despite dose increases High SHBG blunts the bioavailable fraction. Address root causes of elevated SHBG: high-dose oral estrogen therapy (switch to transdermal estrogen), thyroid abnormalities, or caloric restriction. Increasing testosterone dose to override high SHBG often results in high total testosterone without proportional free testosterone gain — a poor trade-off.

Partner or children absorbing topical testosterone from skin contact This is documented. Apply testosterone to a low-contact area (inner thigh, not hand or forearm). Wash hands after application. Cover the site with clothing before contact with children or a partner for at least 2 hours.

Mood worsening on testosterone Rare but reported. Some women are sensitive to androgenic shifts in neurosteroid balance. If anxiety, irritability, or low mood worsens within 4 weeks of starting, pause therapy and reassess. This is not an absolute contraindication, but it warrants a root-cause conversation with your provider.

Tools and Resources

  • Validated symptom tools: Female Sexual Function Index (FSFI), Menopause Rating Scale (MRS), and the Female Sexual Distress Scale (FSDS) — all free and available from their respective academic sources
  • Lab timing: Draw testosterone levels in the morning, 4–6 hours after applying cream, for the most consistent reads
  • Provider search: The Menopause Society (formerly NAMS) maintains a provider finder at menopause.org for US-based clinicians with menopause certification
  • For women managing weight alongside hormonal changes: Medical weight loss for women over 40 covers the interaction between metabolic function and hormonal decline, a common co-occurring concern

What to Do Next

If you've identified with 3 or more symptoms in this guide — low libido, fatigue, brain fog, difficulty building muscle, mood instability — the next step is a complete hormone panel with a provider who interprets female testosterone levels on female-specific reference ranges. Good Life Health's direct primary care model gives you direct access to providers in 2026 who treat hormonal health as a medical priority, not an afterthought.

FAQ

What is testosterone replacement therapy for females used to treat? The strongest evidence supports treatment of hypoactive sexual desire disorder (HSDD). Off-label uses with growing clinical support include fatigue, brain fog, muscle loss, and mood instability — particularly in peri- and post-menopausal women whose testosterone levels have declined.

What are normal testosterone levels for women? Total testosterone in women typically runs 15–70 ng/dL. Free testosterone — the bioavailable fraction — is a more clinically useful number. Labs using male reference ranges (300–1000 ng/dL) will make every woman look normal even when her free testosterone is deficient.

Is testosterone therapy for women FDA-approved? No FDA-approved testosterone product exists specifically for women in the US as of 2026. All female testosterone therapy is prescribed off-label, most commonly as compounded transdermal creams or gels.

How long does testosterone therapy take to work in women? Most women notice changes in energy and libido between weeks 4 and 8. Body composition changes take 3–6 months of consistent dosing to become measurable. Evaluating response before 8–12 weeks is premature.

What are the side effects of testosterone for women? At correct doses, side effects are uncommon. At excessive doses: acne, oily skin, clitoral enlargement, scalp hair thinning, voice deepening, and HDL cholesterol suppression. Most androgenic side effects are dose-related and reversible if caught early — except voice changes, which can be permanent.

Can testosterone therapy cause weight gain in women? Not directly. Testosterone tends to shift body composition toward lean mass and away from fat, particularly in women with low levels. Some women experience water retention early in therapy, which resolves within weeks.

Should women take testosterone with estrogen? In peri- and post-menopausal women, estrogen is typically optimized first. Testosterone is then added when symptoms persist despite adequate estrogen levels. The two hormones have complementary but distinct mechanisms — they are not interchangeable.

How do I find a doctor who prescribes testosterone for women? Look for providers with menopause certification through The Menopause Society or board certification in endocrinology. Direct primary care practices with a hormone focus — like Good Life Health — are increasingly common access points in 2026 for women who can't find knowledgeable providers through standard insurance networks.

One Last Thing

The ovaries produce testosterone until well into the post-menopausal years — which means surgical menopause (bilateral oophorectomy) causes a more abrupt and severe testosterone drop than natural menopause. Women who have had their ovaries removed before age 50 are among the strongest candidates for testosterone therapy, yet this population is among the least likely to be offered it. If this applies to you, bring it up specifically — don't wait for your provider to ask.

Related Guides

References

  1. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. 2015. doi.org/10.1210/jc.2015-2236
  2. Testosterone in Women — The Clinical Significance (Lancet Diabetes & Endocrinology). 2015. doi.org/10.1016/S2213-8587(15)00284-300284-3)